



Centers for Medicare & Medicaid Services

Search

Medicare

Medicaid/CHIP

Medicare-Medicaid
Coordination

Private
Insurance

Innovation
Center

Regulations &
Guidance

Research, Statistics,
Data & Systems

Outreach &
Education

[Home](#) > [Medicare](#) > [Medicare Part B Drug Average Sales Price](#)

Medicare Part B Drug Average Sales Price



[2021 ASP Drug Pricing Files](#)

[2020 ASP Drug Pricing Files](#)

[2019 ASP Drug Pricing Files](#)

[2018 ASP Drug Pricing Files](#)

[2017 ASP Drug Pricing Files](#)

[2016 ASP Drug Pricing Files](#)

[2015 ASP Drug Pricing Files](#)

[2014 ASP Drug Pricing Files](#)

[2013 ASP Drug Pricing Files](#)

[2012 ASP Drug Pricing Files](#)

[2011 ASP Drug Pricing Files](#)

[2010 ASP Drug Pricing Files](#)

[2009 ASP Drug Pricing Files](#)

[2008 ASP Drug Pricing Files](#)

[2007 ASP Drug Pricing Files](#)

[2006 ASP Drug Pricing Files](#)

[2005 ASP Drug Pricing Files](#)

[Medicare Part B Drugs Regulations](#)

[COVID-19 Vaccines and Monoclonal
Antibodies](#)

[Seasonal Influenza Vaccines Pricing](#)

[Blood Clotting Factor Furnishing Fee](#)

[Part B Biosimilar Biological Product](#)

Medicare Part B Drug Average Sales Price

Manufacturer reporting of Average Sales Price (ASP) data

Section 401 of the Consolidated Appropriations Act (CAA), 2021 amended section 1847A of the Social Security Act (the Act) to add new section 1847A(f)(2) of the Act, which requires manufacturers without a Medicaid drug rebate agreement to report average sales price (ASP) information to CMS for calendar quarters beginning on January 1, 2022, for drugs or biologicals payable under Medicare Part B and described in sections 1842(o)(1)(C), (E), or (G) or 1881(b)(14)(B) of the Act, including items, services, supplies, and products that are payable under Part B as a drug or biological. This is discussed in further detail in the Physician Fee Schedule 2022 Final Rule.

Such manufacturers should first report ASP data to CMS for calendar quarters beginning on January 1, 2022. As stated in 42 CFR § 414.804 (which is based on statutory language), the "manufacturer's average sales price must be calculated by the manufacturer every calendar quarter and submitted to CMS within 30 days of the close of the quarter." Therefore, manufacturers first reporting ASP data to CMS in accordance with provisions in section 401 of the CAA, 2021 should do so no later than April 30, 2022 (within 30 days of the close of the first quarter of 2022) for the July 2022 ASP Drug Pricing File.

For instructions regarding ASP reporting, please see the Medicare Part B Drug ASP User Manual, Tips for Successful ASP submission, and visit <https://portal.cms.gov> to register for the online portal system. Other helpful links are available below.

MFN Model

The MFN Model has been announced. More information is available on the MFN webpage (see related links section below).

HCPSC Codes for Which ASP Reporting Is Done in Units of Measure Other Than an NDC

A list of drugs that must be reported in units other than NDCs is posted in the Downloads section. More information is available in the 2012 physician fee schedule final rule (76 FR 73296-8, November 28, 2011).

Medicare Contractor Reporting Template for Medicare Part B Drugs - (Located in the "Downloads" section below)

As indicated in CR 4140, dated February 15, 2006, Medicare contractors shall use the Medicare Contractor Reporting Template for Part B drugs to report information on all Medicare Part B drugs not paid on a cost or prospective payment basis when payment limits are not listed in the quarterly drug pricing files, or in the OPPS Pricer. Contractors shall also use the template to report pricing information for the NOC drug billing codes. This information must be sent to CMS on a monthly basis to e-mail address: sec303aspdata@cms.hhs.gov.